232 related articles for article (PubMed ID: 21886780)
21. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
[TBL] [Abstract][Full Text] [Related]
22. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients.
Valenti L; Girelli D; Valenti GF; Castagna A; Como G; Campostrini N; Rametta R; Dongiovanni P; Messa P; Fargion S
Clin J Am Soc Nephrol; 2009 Aug; 4(8):1331-7. PubMed ID: 19541813
[TBL] [Abstract][Full Text] [Related]
23. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.
Zaritsky J; Young B; Wang HJ; Westerman M; Olbina G; Nemeth E; Ganz T; Rivera S; Nissenson AR; Salusky IB
Clin J Am Soc Nephrol; 2009 Jun; 4(6):1051-6. PubMed ID: 19406957
[TBL] [Abstract][Full Text] [Related]
24. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C.
Fujita N; Sugimoto R; Takeo M; Urawa N; Mifuji R; Tanaka H; Kobayashi Y; Iwasa M; Watanabe S; Adachi Y; Kaito M
Mol Med; 2007; 13(1-2):97-104. PubMed ID: 17515961
[TBL] [Abstract][Full Text] [Related]
25. Levels of soluble forms of ICAM and VCAM in patients with myelodysplastic syndromes and their prognostic significance.
Passam FH; Tsirakis G; Boula A; Fragou A; Consolas I; Alegakis A; Kyriakou DS; Alexandrakis MG
Clin Lab Haematol; 2004 Dec; 26(6):391-5. PubMed ID: 15595996
[TBL] [Abstract][Full Text] [Related]
26. Role of decreased circulating hepcidin concentrations in the iron excess of women with the polycystic ovary syndrome.
Luque-Ramírez M; Álvarez-Blasco F; Alpañés M; Escobar-Morreale HF
J Clin Endocrinol Metab; 2011 Mar; 96(3):846-52. PubMed ID: 21209031
[TBL] [Abstract][Full Text] [Related]
27. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.
Pardanani A; Finke C; Abdelrahman RA; Lasho TL; Tefferi A
Am J Hematol; 2013 Apr; 88(4):312-6. PubMed ID: 23450619
[TBL] [Abstract][Full Text] [Related]
28. [Myelodysplastic syndromes and iron metabolism].
Kawabata H
Rinsho Ketsueki; 2018; 59(10):2042-2049. PubMed ID: 30305507
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
Kim IH; Moon JH; Lim SN; Sohn SK; Kim HG; Lee GW; Kim YS; Lee HS; Kwon KY; Kim SH; Park KT; Chung JS; Lee WS; Lee SM; Hyun MS; Kim H; Ryoo HM; Bae SH; Joo YD
Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
[TBL] [Abstract][Full Text] [Related]
30. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.
van der Weerd NC; Grooteman MP; Bots ML; van den Dorpel MA; den Hoedt CH; Mazairac AH; Nubé MJ; Penne EL; Gaillard CA; Wetzels JF; Wiegerinck ET; Swinkels DW; Blankestijn PJ; Ter Wee PM;
PLoS One; 2012; 7(7):e39783. PubMed ID: 22808058
[TBL] [Abstract][Full Text] [Related]
31. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
32. Serum prohepcidin is associated with soluble transferrin receptor-1 but not ferritin in healthy post-menopausal women.
Huang X; Fung ET; Yip C; Zeleniuch-Jacquotte A
Blood Cells Mol Dis; 2008; 41(3):265-9. PubMed ID: 18694648
[TBL] [Abstract][Full Text] [Related]
33. Is iron overload in alcohol-related cirrhosis mediated by hepcidin?
Iqbal T; Diab A; Ward DG; Brookes MJ; Tselepis C; Murray J; Elias E
World J Gastroenterol; 2009 Dec; 15(46):5864-6. PubMed ID: 19998511
[TBL] [Abstract][Full Text] [Related]
34. Detection of CD55- and CD59-deficient granulocytic populations in patients with myelodysplastic syndrome.
Kaiafa G; Papadopoulos A; Ntaios G; Saouli Z; Savopoulos C; Tsesmeli N; Kontoninas Z; Chatzinikolaou A; Tsavdaridou V; Klonizakis I; Hatzitolios A
Ann Hematol; 2008 Apr; 87(4):257-62. PubMed ID: 18158579
[TBL] [Abstract][Full Text] [Related]
35. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.
Zaritsky J; Young B; Gales B; Wang HJ; Rastogi A; Westerman M; Nemeth E; Ganz T; Salusky IB
Clin J Am Soc Nephrol; 2010 Jun; 5(6):1010-4. PubMed ID: 20299375
[TBL] [Abstract][Full Text] [Related]
36. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights.
Rhodes CJ; Howard LS; Busbridge M; Ashby D; Kondili E; Gibbs JS; Wharton J; Wilkins MR
J Am Coll Cardiol; 2011 Jul; 58(3):300-9. PubMed ID: 21737024
[TBL] [Abstract][Full Text] [Related]
37. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
[TBL] [Abstract][Full Text] [Related]
38. Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia.
Matsumoto M; Tsujino T; Lee-Kawabata M; Naito Y; Akahori H; Sakoda T; Ohyanagi M; Tomosugi N; Masuyama T
Circ J; 2010 Feb; 74(2):301-6. PubMed ID: 20019408
[TBL] [Abstract][Full Text] [Related]
39. Blunted increase in serum hepcidin as response to oral iron in HFE-hemochromatosis.
Sangwaiya A; Manglam V; Busbridge M; Thursz M; Arnold J
Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):721-4. PubMed ID: 21654321
[TBL] [Abstract][Full Text] [Related]
40. Hepcidin concentrations and iron homeostasis in preeclampsia.
Toldi G; Stenczer B; Molvarec A; Takáts Z; Beko G; Rigó J; Vásárhelyi B
Clin Chem Lab Med; 2010 Oct; 48(10):1423-6. PubMed ID: 20626300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
